Pune's Serum Institute of India applies for permission to start trials of 'Covovax' vaccine

The company is aiming to launch the vaccine being produced in collaboration with American vaccine development company Novavax by June 2021, SII CEO Adar Poonawalla said

Press Trust of India January 30, 2021 18:18:25 IST
Pune's Serum Institute of India applies for permission to start trials of 'Covovax' vaccine

Representational image. PTI

Pune: Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said his company has applied to start the trials of another COVID-19 vaccine and that it hopes to launch it by June 2021.

The city-based firm has already produced 'Covishield' vaccine, co-developed by the University of Oxford and British-Swedish company AstraZeneca. The Centre has purchased 11 million doses of Covishield vaccine for the ongoing inoculation drive.

In a tweet, Poonawalla said, "Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!"

The country launched its COVID-19 vaccination drive from 16 January in what Prime Minister Narendra Modi has called the world's largest inoculation programme with priority to be given to nearly three crore healthcare and frontline workers.

Updated Date:

Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply

also read

Harsh Vardhan says India on threshold of complete inoculation; over 8.8 mn covered so far
India

Harsh Vardhan says India on threshold of complete inoculation; over 8.8 mn covered so far

The Union Health Minister added that India had successfully curbed the number of cases per million population despite many constraints

Recent surge in Maharashtra offers clues of how COVID-19 pandemic may move through rest of India
India

Recent surge in Maharashtra offers clues of how COVID-19 pandemic may move through rest of India

In October 2020, Mumbai appeared to show the future pathway — and potential end-point — for the COVID-19 pandemic. That certainty has been irreparably dented

COVID-19 variants: EU to launch incubator for 'second gen' vaccines against future strains
World

COVID-19 variants: EU to launch incubator for 'second gen' vaccines against future strains

The 'HERA incubator' will bring together the pharmaceutical industry, laboratories, health authorities and researchers, a spokesperson said.